IL178479A - Preparations capable of assisting penetration through a biological barrier and methods of preparation - Google Patents
Preparations capable of assisting penetration through a biological barrier and methods of preparationInfo
- Publication number
- IL178479A IL178479A IL178479A IL17847906A IL178479A IL 178479 A IL178479 A IL 178479A IL 178479 A IL178479 A IL 178479A IL 17847906 A IL17847906 A IL 17847906A IL 178479 A IL178479 A IL 178479A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- producing same
- compositions capable
- biological barrier
- facilitating penetration
- Prior art date
Links
- 230000004888 barrier function Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000035515 penetration Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56234504P | 2004-04-15 | 2004-04-15 | |
| PCT/IB2005/004183 WO2006097793A2 (en) | 2004-04-15 | 2005-04-14 | Compositions capable of facilitating penetration across a biological barrier |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL178479A0 IL178479A0 (en) | 2007-02-11 |
| IL178479A true IL178479A (en) | 2015-11-30 |
Family
ID=36822392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL178479A IL178479A (en) | 2004-04-15 | 2006-10-05 | Preparations capable of assisting penetration through a biological barrier and methods of preparation |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20050232981A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1742663A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2007532629A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20070044805A (cg-RX-API-DMAC10.html) |
| CN (1) | CN101084016A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2005329255B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2563533C (cg-RX-API-DMAC10.html) |
| IL (1) | IL178479A (cg-RX-API-DMAC10.html) |
| MX (1) | MXPA06011871A (cg-RX-API-DMAC10.html) |
| NZ (1) | NZ550320A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2006097793A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (184)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658938B2 (en) * | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| SI1509618T1 (sl) * | 2002-05-13 | 2009-02-28 | Arexis Ab | Avtoimunska stanja in defekti NADPH oksidaze |
| US20070219131A1 (en) * | 2004-04-15 | 2007-09-20 | Ben-Sasson Shmuel A | Compositions capable of facilitating penetration across a biological barrier |
| CA2563533C (en) * | 2004-04-15 | 2013-10-01 | Shmuel A. Ben-Sasson | Compositions capable of facilitating penetration across a biological barrier |
| GB0427267D0 (en) * | 2004-12-13 | 2005-01-12 | Maria Teresa De Magistris | Peptide adjuvants |
| WO2007022345A2 (en) * | 2005-08-17 | 2007-02-22 | Fleming And Company, Pharmaceuticals | Vitamin b12 nasal spray and method of use |
| EP2722054B1 (en) * | 2005-09-06 | 2018-03-21 | Oramed Pharmaceuticals Inc. | Methods and compositions for oral administration of proteins |
| JP5713534B2 (ja) * | 2005-10-07 | 2015-05-07 | ザ ユニバーシティ オブ アラバマ | 多機能イオン性液体組成物 |
| US20080051451A1 (en) * | 2006-03-15 | 2008-02-28 | Marcel Linschoten | Autoimmune conditions and NADPH oxidase defects |
| WO2007104790A1 (en) * | 2006-03-15 | 2007-09-20 | Biovitrum Ab (Publ) | Autoimmune conditions and nadph oxidase defects |
| BRPI0710503A2 (pt) * | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| EP2918276A1 (en) * | 2006-05-30 | 2015-09-16 | Orahealth Corporation | Cobalamin compositions and methods for treating or preventing mucositis |
| JP2010520852A (ja) * | 2006-10-27 | 2010-06-17 | ジュセッペ・トリジャンテ | 除毛(脱毛)のための化合物と方法 |
| US9918934B2 (en) | 2006-12-12 | 2018-03-20 | Edgar Joel Acosta-Zara | Linker-based lecithin microemulsion delivery vehicles |
| DE102007012644A1 (de) * | 2007-03-16 | 2008-09-18 | Bayer Healthcare Ag | Stabilisierung von Vitamin B12 |
| WO2008132732A2 (en) * | 2007-04-26 | 2008-11-06 | Oramed Pharmaceuticals Inc | Methods and compositions for rectal administration of proteins |
| DK2152293T3 (en) * | 2007-05-11 | 2017-02-06 | Univ Nebraska | COMPOSITIONS FOR PROTEIN GIVING AND PROCEDURES FOR USE THEREOF |
| AU2008257505B2 (en) * | 2007-06-01 | 2013-05-16 | Novo Nordisk A/S | Stable non-aqueous pharmaceutical compositions |
| EP2514406A1 (en) * | 2007-06-01 | 2012-10-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| EP2679224A1 (en) | 2007-08-01 | 2014-01-01 | University of Pittsburgh of the Commonwealth System of Higher Education | Nitro oleic acid modulation of type II diabetes |
| US8044021B2 (en) * | 2007-09-20 | 2011-10-25 | Abbott Cardiovascular Systems Inc. | Sustained release of apo A-I mimetic peptides and methods of treatment |
| US8101565B2 (en) * | 2007-09-20 | 2012-01-24 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US9173890B2 (en) * | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US7985727B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Apo A-I mimetic peptides and methods of treatment |
| US7985728B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| ES2588705T3 (es) | 2007-09-27 | 2016-11-04 | Immunovaccine Technologies Inc. | Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo |
| IL188647A0 (en) | 2008-01-08 | 2008-11-03 | Orina Gribova | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
| HUE032284T2 (en) | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
| RU2504373C2 (ru) * | 2008-03-26 | 2014-01-20 | ОРАМЕД Лтд. | Способы и композиции для перорального введения протеинов |
| US20090258889A1 (en) * | 2008-04-11 | 2009-10-15 | Whitmire Micro-Gen Research Laboratories, Inc. | Pesticidal compositions |
| DK2280928T3 (en) | 2008-05-01 | 2018-11-05 | Complexa Inc | Vinyl-substituted fatty acids |
| CA2723434C (en) | 2008-05-05 | 2018-01-23 | Oramed Ltd. | Methods and compositions for oral administration of exenatide |
| US20090280169A1 (en) * | 2008-05-07 | 2009-11-12 | Merrion Research Iii Limited | Compositions of peptides and processes of preparation thereof |
| CA2723918C (en) | 2008-06-05 | 2018-01-09 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
| US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
| CN102099024B (zh) | 2008-06-19 | 2015-11-25 | 犹他大学研究基金会 | 硝化脂质在毒性医疗疗法的副作用的治疗上的用途 |
| CN102123697B (zh) * | 2008-08-18 | 2015-06-10 | 安特拉贝欧有限公司 | 用于口服给予蛋白质的方法和组合物 |
| MX2011002688A (es) * | 2008-09-12 | 2011-04-12 | Critical Pharmaceuticals Ltd | Mejoramientos en la absorcion de agentes terapeuticos a traves de las membranas mucosas o la piel. |
| RU2678833C2 (ru) * | 2008-09-17 | 2019-02-04 | Киазма Инк. | Фармацевтические композиции и соответствующие способы доставки |
| CN103589529A (zh) * | 2008-11-13 | 2014-02-19 | 诺维信公司 | 洗涤剂组合物 |
| CN102395274B (zh) | 2009-02-13 | 2014-03-12 | 托派卡医药股份有限公司 | 抗真菌制剂 |
| CN101862445A (zh) * | 2009-04-16 | 2010-10-20 | 哈药集团生物工程有限公司 | 一种含有蛋白酶抑制剂的口服胰岛素 |
| IN2012DN00311A (cg-RX-API-DMAC10.html) | 2009-07-09 | 2015-05-08 | Oshadi Drug Administration Ltd | |
| CA2769624C (en) | 2009-07-31 | 2018-09-11 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Electrophilic fatty acid derivatives as anti-inflammatory agents |
| EP2921486B1 (en) | 2009-08-07 | 2017-09-27 | American Life Science Pharmaceuticals, Inc. | Compositions and methods for treating beta-amyloid related diseases |
| WO2011041639A2 (en) | 2009-10-02 | 2011-04-07 | Miller Raymond A | Heteroatom containing substituted fatty acids |
| WO2011116139A2 (en) * | 2010-03-16 | 2011-09-22 | Chiasma Inc. | Improved pharmaceutical compositions and methods of delivery |
| US9089484B2 (en) | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
| EP2590643A4 (en) * | 2010-06-28 | 2014-01-01 | Complexa Inc | MEDICINAL PRODUCT MADE FROM SEVERAL INGREDIENTS FOR THE TREATMENT OF DIABETES |
| CA2808978A1 (en) | 2010-08-23 | 2012-03-01 | Shmuel Ben-Sasson | Compositions for gastric delivery of active agents |
| CN102466730A (zh) * | 2010-11-19 | 2012-05-23 | 南京神州英诺华医疗科技有限公司 | 一种新的配制血型反定型试剂的方法 |
| US8455436B2 (en) | 2010-12-28 | 2013-06-04 | Depuy Mitek, Llc | Compositions and methods for treating joints |
| US8398611B2 (en) | 2010-12-28 | 2013-03-19 | Depuy Mitek, Inc. | Compositions and methods for treating joints |
| US8524662B2 (en) | 2010-12-28 | 2013-09-03 | Depuy Mitek, Llc | Compositions and methods for treating joints |
| EP2661273A4 (en) | 2011-01-07 | 2014-06-04 | Merrion Res Iii Ltd | IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION |
| EP2678002A2 (en) | 2011-02-25 | 2014-01-01 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure |
| US9498533B2 (en) | 2011-04-04 | 2016-11-22 | Board Of Regents Of The University Of Nebraska | Drug delivery compositions and methods |
| US8623839B2 (en) | 2011-06-30 | 2014-01-07 | Depuy Mitek, Llc | Compositions and methods for stabilized polysaccharide formulations |
| EP2744491B1 (en) | 2011-08-19 | 2020-07-29 | The University of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
| EP2750697A4 (en) | 2011-09-02 | 2015-03-25 | Medtronic Inc | CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF |
| JP6000956B2 (ja) * | 2011-09-13 | 2016-10-05 | オリンパス株式会社 | 膵液成分を含有する生体試料中のプロテアーゼの阻害方法 |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| WO2013102899A1 (en) | 2012-01-03 | 2013-07-11 | Oramed Ltd. | Methods and compositions for treating diabetes |
| ES2912138T3 (es) | 2012-02-01 | 2022-05-24 | Oramed Ltd | Composiciones que contienen inhibidores de proteasa, composiciones que comprenden las mismas y métodos para producir y usar las misma |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| KR102236462B1 (ko) | 2012-03-19 | 2021-04-08 | 시다라 세라퓨틱스, 인코포레이티드 | 에키노칸딘 계열의 화합물에 대한 투여 용법 |
| CN104411338A (zh) | 2012-04-02 | 2015-03-11 | 现代治疗公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| EP2836508B1 (en) | 2012-04-11 | 2016-06-29 | Novo Nordisk A/S | Insulin formulations |
| WO2013166408A1 (en) | 2012-05-03 | 2013-11-07 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US9056057B2 (en) | 2012-05-03 | 2015-06-16 | Kala Pharmaceuticals, Inc. | Nanocrystals, compositions, and methods that aid particle transport in mucus |
| CN104395749B (zh) * | 2012-06-22 | 2016-12-28 | 奥林巴斯株式会社 | 含胰液成分的试样的调制方法、以及含胰液成分的生物试样的室温储存用试剂盒 |
| WO2014030052A2 (en) * | 2012-08-21 | 2014-02-27 | Glaxo Group Limited | Compositions comprising an antibody and camostat mesylate (cm) |
| CN102940886B (zh) * | 2012-12-13 | 2015-02-18 | 鼎正动物药业(天津)有限公司 | 一种生物屏障渗透剂及其制备方法 |
| CN104902921A (zh) | 2013-01-03 | 2015-09-09 | 奥拉姆德有限公司 | 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物 |
| US9353122B2 (en) | 2013-02-15 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| US9353123B2 (en) | 2013-02-20 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| CN105338962A (zh) * | 2013-03-12 | 2016-02-17 | 应用生物学研究有限公司 | 用于改善的药物递送的螯合栓剂 |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| EP3003267A1 (en) * | 2013-05-30 | 2016-04-13 | Novo Nordisk A/S | Novel oral pharmaceutical composition for treatment of diabetes |
| CN103301064B (zh) * | 2013-06-04 | 2016-04-20 | 北京四环生物制药有限公司 | 一种白介素-2或其衍生物鼻喷剂及其制备方法 |
| WO2015016682A1 (ko) | 2013-08-01 | 2015-02-05 | 경희대학교 산학협력단 | 당뇨병 예방 또는 치료용 약학적 조성물, 당뇨병 예방 또는 치료 방법, 및 당뇨병 치료제 스크리닝 방법 |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| CA2923029A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| KR20160099084A (ko) | 2013-11-01 | 2016-08-19 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정질 형태 및 그의 용도 |
| KR101470793B1 (ko) | 2014-06-30 | 2014-12-08 | 순천향대학교 산학협력단 | 흡수촉진제로서의 펩타이드와 이를 포함하는 조성물 |
| WO2016011226A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| EP3171895A1 (en) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| EP3229824A4 (en) | 2014-12-10 | 2018-07-11 | Chiasma Inc. | Oral octreotide administered in combination with other therapeutic agents |
| US9682099B2 (en) | 2015-01-20 | 2017-06-20 | DePuy Synthes Products, Inc. | Compositions and methods for treating joints |
| JP7211704B2 (ja) | 2015-01-29 | 2023-01-24 | ノヴォ ノルディスク アー/エス | Glp-1アゴニスト及び腸溶コーティングを含む錠剤 |
| SI3253401T1 (sl) | 2015-02-03 | 2025-07-31 | Amryt Endo, Inc. | Zdravljenje akromegalije z oralnim oktreotidom |
| CA2990521C (en) | 2015-07-07 | 2023-10-10 | H. Lundbeck A/S | Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases |
| CN113440506A (zh) | 2015-10-02 | 2021-09-28 | 康普莱克夏公司 | 使用治疗有效量的活化脂肪酸预防、治疗和逆转疾病 |
| SG11201803360UA (en) | 2015-10-22 | 2018-05-30 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| PE20181531A1 (es) | 2015-10-22 | 2018-09-26 | Modernatx Inc | Vacuna del virus herpes simple |
| US20180271970A1 (en) | 2015-10-22 | 2018-09-27 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| DE20164728T1 (de) | 2015-10-22 | 2021-09-30 | Modernatx, Inc. | Impfstoffe gegen atemwegsvirus |
| MA46023A (fr) | 2015-10-22 | 2019-07-03 | Modernatx Inc | Vaccin contre le virus de la grippe à large spectre |
| SMT202200310T1 (it) | 2015-12-23 | 2022-09-14 | Modernatx Inc | Metodi di utilizzo dei polinucleotidi codificanti il ligando di ox40 |
| US20190241658A1 (en) | 2016-01-10 | 2019-08-08 | Modernatx, Inc. | Therapeutic mRNAs encoding anti CTLA-4 antibodies |
| WO2018048750A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| ES2886837T3 (es) | 2016-12-16 | 2021-12-21 | Novo Nordisk As | Composiciones farmacéuticas que contienen insulina |
| AU2018270111B2 (en) | 2017-05-18 | 2022-07-14 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| EP4253544A3 (en) | 2017-05-18 | 2023-12-20 | ModernaTX, Inc. | Modified messenger rna comprising functional rna elements |
| EP3638292A1 (en) | 2017-06-14 | 2020-04-22 | ModernaTX, Inc. | Polynucleotides encoding coagulation factor viii |
| WO2019094702A1 (en) | 2017-11-10 | 2019-05-16 | Cocoon Biotech Inc. | Ocular applications of silk-based products |
| EP3714048B1 (en) | 2017-11-22 | 2025-04-09 | ModernaTX, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
| JP7424976B2 (ja) | 2017-11-22 | 2024-01-30 | モダーナティエックス・インコーポレイテッド | プロピオン酸血症の治療用のプロピオニルCoAカルボキシラーゼアルファ及びベータサブユニットをコードするポリヌクレオチド |
| US11939601B2 (en) | 2017-11-22 | 2024-03-26 | Modernatx, Inc. | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
| WO2019133890A1 (en) * | 2017-12-29 | 2019-07-04 | University Of Kansas | Nanoparticles including a glatiramoid useful in polynucleotide delivery |
| US11802146B2 (en) | 2018-01-05 | 2023-10-31 | Modernatx, Inc. | Polynucleotides encoding anti-chikungunya virus antibodies |
| WO2019157453A1 (en) * | 2018-02-12 | 2019-08-15 | Trilogy Therapeutics, Inc. | Caspofungin compositions for inhalation |
| JP7256816B2 (ja) * | 2018-03-07 | 2023-04-12 | コメラ ライフ サイエンシズ,インコーポレイテッド | タンパク質製剤用の賦形剤化合物 |
| US20210163928A1 (en) | 2018-04-11 | 2021-06-03 | Modernatx, Inc. | Messenger rna comprising functional rna elements |
| MA52709A (fr) | 2018-05-23 | 2021-03-31 | Modernatx Inc | Administration d'adn |
| BR112020024019A2 (pt) | 2018-05-25 | 2021-02-23 | Imara Inc. | monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona |
| JP2021526126A (ja) * | 2018-06-23 | 2021-09-30 | ポビバ コーポレーションPoviva Corp. | 血液脳関門を通した親油性活性薬剤の送達の向上と中枢神経系障害を処置する為の方法 |
| WO2020023390A1 (en) | 2018-07-25 | 2020-01-30 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| WO2020033791A1 (en) | 2018-08-09 | 2020-02-13 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| KR20250108770A (ko) | 2018-08-31 | 2025-07-15 | 카듀리온 파마슈티칼스, 인크. | 겸상 세포 질환의 치료를 위한 pde9 억제제 |
| MA53545A (fr) | 2018-09-02 | 2021-07-14 | Modernatx Inc | Polynucléotides codant pour l'acyl-coa déshydrogénase à très longue chaîne pour le traitement de l'insuffisance en acyl-coa déshydrogénase à très longue chaîne |
| JP2022500436A (ja) | 2018-09-13 | 2022-01-04 | モダーナティエックス・インコーポレイテッドModernaTX, Inc. | 糖原病を処置するためのグルコース−6−ホスファターゼをコードするポリヌクレオチド |
| US12644102B2 (en) | 2018-09-13 | 2026-06-02 | Modernatx, Inc. | Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex E1-α, E1-β, and E2 subunits for the treatment of maple syrup urine disease |
| MA53615A (fr) | 2018-09-14 | 2021-07-21 | Modernatx Inc | Polynucléotides codant pour le polypeptide a1, de la famille de l'uridine diphosphate glycosyltransférase 1, pour le traitement du syndrome de crigler-najjar |
| WO2020069169A1 (en) | 2018-09-27 | 2020-04-02 | Modernatx, Inc. | Polynucleotides encoding arginase 1 for the treatment of arginase deficiency |
| US20220001026A1 (en) | 2018-11-08 | 2022-01-06 | Modernatx, Inc. | Use of mrna encoding ox40l to treat cancer in human patients |
| GB201900728D0 (en) * | 2019-01-18 | 2019-03-06 | Univ Birmingham | Drug delivery system |
| WO2020227615A1 (en) | 2019-05-08 | 2020-11-12 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
| WO2020227642A1 (en) | 2019-05-08 | 2020-11-12 | Modernatx, Inc. | Compositions for skin and wounds and methods of use thereof |
| MA56517A (fr) | 2019-06-24 | 2022-04-27 | Modernatx Inc | Arn messager comprenant des éléments d'arn fonctionnels et leurs utilisations |
| EP3987027A1 (en) | 2019-06-24 | 2022-04-27 | ModernaTX, Inc. | Endonuclease-resistant messenger rna and uses thereof |
| AU2020355000A1 (en) | 2019-09-23 | 2022-03-17 | Sepia Therapeutics, Inc. | Compositions and methods for modulating apolipoprotein B (APOB) gene expression |
| CN114729376A (zh) | 2019-09-23 | 2022-07-08 | 欧米茄治疗公司 | 用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法 |
| AU2021206286A1 (en) | 2020-01-10 | 2024-08-08 | Consynance Therapeutics, Inc. | Therapeutic combinations of drugs and methods of using them |
| AU2021213767A1 (en) | 2020-01-28 | 2022-07-28 | Genentech, Inc. | IL15/IL15R alpha heterodimeric Fc-fusion proteins for the treatment of cancer |
| WO2021183720A1 (en) | 2020-03-11 | 2021-09-16 | Omega Therapeutics, Inc. | Compositions and methods for modulating forkhead box p3 (foxp3) gene expression |
| AU2021285812A1 (en) | 2020-06-01 | 2023-01-05 | Modernatx, Inc. | Phenylalanine hydroxylase variants and uses thereof |
| JP2023533174A (ja) | 2020-06-12 | 2023-08-02 | ユニバーシティ オブ ロチェスター | ACE-tRNAのコード化及び発現 |
| CA3199784A1 (en) | 2020-11-13 | 2022-05-19 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| WO2022204380A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof |
| US20240189449A1 (en) | 2021-03-24 | 2024-06-13 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency |
| WO2022204369A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
| WO2022204390A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof |
| US20240207374A1 (en) | 2021-03-24 | 2024-06-27 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
| US20240384277A1 (en) | 2021-06-15 | 2024-11-21 | Modernatx, Inc. | Engineered polynucleotides for cell-type or microenvironment-specific expression |
| US20240376445A1 (en) | 2021-06-22 | 2024-11-14 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
| WO2023283359A2 (en) | 2021-07-07 | 2023-01-12 | Omega Therapeutics, Inc. | Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression |
| WO2023004113A2 (en) | 2021-07-22 | 2023-01-26 | The Regents Of The University Of California | Compositions and methods for using purified human rna editing enzymes |
| US20250017867A1 (en) | 2021-10-01 | 2025-01-16 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease |
| AU2023215397A1 (en) | 2022-02-07 | 2024-08-22 | University Of Rochester | Optimized sequences for enhanced trna expression or/and nonsense mutation suppression. |
| US20250327041A1 (en) | 2022-02-24 | 2025-10-23 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| WO2023177904A1 (en) | 2022-03-18 | 2023-09-21 | Modernatx, Inc. | Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications |
| WO2023183909A2 (en) | 2022-03-25 | 2023-09-28 | Modernatx, Inc. | Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia |
| WO2023196399A1 (en) | 2022-04-06 | 2023-10-12 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria |
| WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
| CN114948913B (zh) * | 2022-05-10 | 2024-10-15 | 苏州大学 | 一种具有生物粘附性的凝胶薄膜及其应用 |
| CN119630685A (zh) | 2022-06-13 | 2025-03-14 | B.A.I.实验室有限责任公司 | 结合白介素-13的环状寡肽及其使用方法 |
| CN114933736B (zh) * | 2022-06-17 | 2023-02-10 | 江南大学 | 一种多响应性神经支架材料及其制备方法与应用 |
| WO2024010379A1 (ko) * | 2022-07-05 | 2024-01-11 | 주식회사 지투지바이오 | 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방성 미립구 제제 및 이의 제조방법 |
| EP4562163A1 (en) | 2022-07-26 | 2025-06-04 | ModernaTX, Inc. | Engineered polynucleotides for temporal control of expression |
| WO2024044147A1 (en) | 2022-08-23 | 2024-02-29 | Modernatx, Inc. | Methods for purification of ionizable lipids |
| WO2024097639A1 (en) | 2022-10-31 | 2024-05-10 | Modernatx, Inc. | Hsa-binding antibodies and binding proteins and uses thereof |
| US20260191905A1 (en) | 2022-12-01 | 2026-07-09 | Modernatx, Inc. | Gpc3-specific antibodies, binding domains, and related proteins and uses thereof |
| WO2024130158A1 (en) | 2022-12-16 | 2024-06-20 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease |
| WO2024182301A2 (en) | 2023-02-27 | 2024-09-06 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding galactose-1-phosphate uridylyltransferase (galt) for the treatment of galactosemia |
| WO2024197033A1 (en) | 2023-03-21 | 2024-09-26 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of heart failure |
| EP4704816A1 (en) | 2023-05-03 | 2026-03-11 | ModernaTX, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| EP4716741A2 (en) | 2023-05-23 | 2026-04-01 | Flagship Labs 114, Inc. | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression |
| EP4520345A1 (en) | 2023-09-06 | 2025-03-12 | Myneo Nv | Product |
| WO2025072482A1 (en) | 2023-09-27 | 2025-04-03 | Modernatx, Inc. | Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof |
| WO2025101685A1 (en) | 2023-11-09 | 2025-05-15 | University Of Rochester | Suppression of nonsense mutations using anticodon engineered (ace)-trnas |
| WO2025255199A1 (en) | 2024-06-05 | 2025-12-11 | Modernatx, Inc. | Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof |
| WO2026030209A1 (en) | 2024-07-29 | 2026-02-05 | University Of Rochester | Use of decoding trnas to boost protein expression or function |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE376722B (cg-RX-API-DMAC10.html) | 1971-03-30 | 1975-06-09 | S E Friberg | |
| BE795516A (fr) * | 1972-02-17 | 1973-08-16 | Ciba Geigy | Preparations de peptides huileuses et injectables et procede pour leur preparation |
| US4489097A (en) | 1976-07-28 | 1984-12-18 | The Procter & Gamble Company | Intravenous solutions with antimicrobial agent |
| JPS53107408A (en) | 1977-02-28 | 1978-09-19 | Yamanouchi Pharmaceut Co Ltd | Micellar preparation for rectal infusion |
| GB2051574B (en) | 1979-05-10 | 1984-01-18 | Kyoto Pharma Ind | Adjuvant for promoting absorption of pharmacologically active substances through the rectum |
| US4572915A (en) | 1984-05-01 | 1986-02-25 | Bioglan Laboratories | Clear micellized solutions of fat soluble essential nutrients |
| US4985404A (en) * | 1984-10-04 | 1991-01-15 | Monsanto Company | Prolonged release of biologically active polypeptides |
| US4650665A (en) | 1985-02-08 | 1987-03-17 | Ethicon, Inc. | Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition |
| DE3709861A1 (de) | 1987-03-25 | 1988-10-06 | Henkel Kgaa | Emulgierende suppositoriengrundmassen und daraus hergestellte zaepfchen |
| DE3738236A1 (de) | 1987-11-11 | 1989-05-24 | Euro Celtique Sa | Beisskapsel |
| FR2627696B1 (fr) | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
| NZ228285A (en) | 1988-03-11 | 1991-08-27 | Teikoku Seiyaku Kk | Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration |
| GB8822857D0 (en) * | 1988-09-29 | 1988-11-02 | Patralan Ltd | Pharmaceutical formulations |
| NZ233403A (en) | 1989-04-28 | 1992-09-25 | Mcneil Ppc Inc | Simulated capsule-like medicament |
| CA2063791C (en) | 1989-08-17 | 2000-12-19 | Michael John Story | Hard gelatine capsule containing fat-soluble nutrients. |
| US5665384A (en) | 1990-04-06 | 1997-09-09 | Rhone-Poulenc Rorer S.A. | Oily capsules of ketoprofen |
| SE9003100D0 (sv) | 1990-09-28 | 1990-09-28 | Kabivitrum Ab | Lipid formulation system |
| IT1243435B (it) | 1990-10-05 | 1994-06-10 | Altergon Sa | Composizioni farmaceutiche per uso topico comprendenti acido ialuronico sale sodico e sostanze disinfettanti |
| US5254331A (en) | 1991-09-12 | 1993-10-19 | Chanel, Inc. | Skin cream composition |
| US5491171A (en) | 1991-11-08 | 1996-02-13 | Kyoto Pharmaceutical Industries, Ltd. | Pharmaceutical preparation containing prostaglandin compound for rectal or vaginal administration |
| US5206219A (en) * | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
| US5478577A (en) | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US5246716A (en) | 1992-01-10 | 1993-09-21 | W. Neudorff Gmbh Kg | Fatty acid-based antifungal composition having residual activity |
| IL103224A (en) | 1992-09-18 | 1998-08-16 | Teva Pharma | Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3 |
| US5288492A (en) | 1992-11-13 | 1994-02-22 | Morris Michael A | Decongestant composition containing aloe vera |
| DK17093D0 (da) | 1993-02-15 | 1993-02-15 | Lyfjathroun H F | Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder |
| IT1263840B (it) | 1993-03-30 | 1996-09-04 | Giuseppe Furiosi | Formulazioni orali di ubidecarenone in forma di capsule |
| US5318781A (en) | 1993-04-06 | 1994-06-07 | Hoffmann-La Roche Inc. | Absorption enhancement of antibiotics |
| SE9302135D0 (sv) | 1993-06-18 | 1993-06-18 | Kabi Pharmacia Ab | New pharmaceutical composition |
| TW402506B (en) | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
| US5506203C1 (en) | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
| US5462726A (en) | 1993-12-17 | 1995-10-31 | Bristol-Myers Squibb Company | Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents |
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| US5561115A (en) | 1994-08-10 | 1996-10-01 | Bayer Corporation | Low temperature albumin fractionation using sodium caprylate as a partitioning agent |
| GB9417524D0 (en) | 1994-08-31 | 1994-10-19 | Cortecs Ltd | Pharmaceutical compositions |
| CA2209016A1 (en) | 1994-12-28 | 1996-07-04 | Teikoku Hormone Mfg. Co., Ltd. | Pharmaceutics for mucosal administration |
| US5827534A (en) | 1995-05-24 | 1998-10-27 | University Of Maryland At Baltimore | Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery |
| US6696413B2 (en) | 1995-06-16 | 2004-02-24 | Hexal Ag | Pharmaceutical preparation with cyclosporin A |
| GB9516268D0 (en) | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
| US5686488A (en) | 1995-08-25 | 1997-11-11 | Alcon Laboratories, Inc. | Polyethoxylated castor oil products as anti-inflammatory agents |
| EP0760237A1 (en) | 1995-08-30 | 1997-03-05 | Cipla Limited | Oil-in-water microemulsions |
| US5665711A (en) | 1995-12-12 | 1997-09-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Antitumor composition for oral administration |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US6280745B1 (en) | 1997-12-23 | 2001-08-28 | Alliance Pharmaceutical Corp. | Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions |
| US5726154A (en) * | 1996-06-28 | 1998-03-10 | University Of Utah Research Foundation | Stabilization and oral delivery of calcitonin |
| US6255502B1 (en) | 1996-07-11 | 2001-07-03 | Farmarc Nederland B.V. | Pharmaceutical composition containing acid addition salt of basic drug |
| US6512010B1 (en) | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
| US5760096A (en) | 1996-10-18 | 1998-06-02 | Thornfeldt; Carl R. | Potent penetration enhancers |
| JPH10265380A (ja) | 1997-03-17 | 1998-10-06 | Bristol Myers Squibb Co | 抗ガン剤 |
| ATE286715T1 (de) | 1997-03-25 | 2005-01-15 | Takeda Chemical Industries Ltd | Gastrointestinale an der mucosa haftende pharmazeutische zusammensetzung |
| EP0878197B1 (en) | 1997-05-14 | 2002-08-21 | Senju Pharmaceutical Co., Ltd. | Compositions containing difluprednate |
| IT1296914B1 (it) | 1997-12-01 | 1999-08-03 | Maria Rosa Gasco | Composizione farmaceutica comprendente microparticelle atte al passaggio transmucosale ed al superamento della barriera |
| IL123143A (en) | 1998-02-02 | 2001-08-26 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing mupirocin |
| JPH11246439A (ja) | 1998-03-02 | 1999-09-14 | Hisamitsu Pharmaceut Co Inc | 経粘膜用吸収促進剤 |
| KR20010041696A (ko) | 1998-03-11 | 2001-05-25 | 그레랑 파마수티컬 가부시키가이샤 | 발포성 장용(腸溶) 제제 |
| DE69902713T2 (de) | 1998-04-14 | 2003-05-28 | Hisamitsu Pharmaceutical Co., Inc. | Die Verwendung eines GP IIb/IIIa Antagonisten für die Herstellung eines Medikamentes geeignet zur transdermalen Applikation mittels Iontophorese |
| IT1302682B1 (it) | 1998-10-16 | 2000-09-29 | Formenti Farmaceutici Spa | Composizioni farmaceutiche orali contenenti buprenorfina |
| GB9823246D0 (en) | 1998-10-24 | 1998-12-16 | Danbiosyst Uk | A nasal drug delivery composition |
| US6838091B2 (en) | 1998-12-18 | 2005-01-04 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
| US6368622B2 (en) | 1999-01-29 | 2002-04-09 | Abbott Laboratories | Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption |
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| DE60038097T2 (de) | 1999-02-22 | 2009-02-12 | Merrion Research I Ltd. | Feste orale dosierungsform enthaltend einen resorptionsverstärker |
| US8119159B2 (en) | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| US20070148228A1 (en) | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6383527B1 (en) | 1999-03-04 | 2002-05-07 | Nps Pharmaceuticals, Inc. | Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID |
| US6632443B2 (en) * | 2000-02-23 | 2003-10-14 | National Research Council Of Canada | Water-soluble compositions of bioactive lipophilic compounds |
| FR2803202B1 (fr) * | 2000-01-03 | 2004-04-16 | Capsulis | Compositions pharmaceutiques destinees a une adminstration par voie orale |
| CN1141974C (zh) | 2000-06-07 | 2004-03-17 | 张昊 | 结肠定位释放的口服生物制剂 |
| US6664234B1 (en) * | 2000-06-30 | 2003-12-16 | Monsanto Technology Llc | Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin |
| FR2811571B1 (fr) | 2000-07-11 | 2002-10-11 | Flamel Tech Sa | Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif |
| US20020091623A1 (en) * | 2000-12-04 | 2002-07-11 | Daniels Alan F. | System and methods for an electronic real estate trading environment |
| DK1900364T3 (da) | 2001-04-18 | 2014-01-13 | Prometic Biosciences Inc | Fedtsyrer, glycerider og analoger med medium kædelængde som neutrofile overlevelses- og aktiveringsfaktorer |
| ATE547095T1 (de) | 2001-05-11 | 2012-03-15 | Isis Pharmaceuticals Inc | Antisense-permeationsverstärker |
| US6528667B2 (en) | 2001-05-14 | 2003-03-04 | Phoenix Research Corporation | Phosphated castor oil and derivatives |
| US20030070584A1 (en) | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
| ES2739852T3 (es) | 2001-07-06 | 2020-02-04 | Veloxis Pharmaceuticals As | Aglomeración controlada |
| US6720002B2 (en) | 2001-07-20 | 2004-04-13 | R.P. Scherer Technologies, Inc. | Antihistamine formulations for soft capsule dosage forms |
| CN1335182A (zh) * | 2001-08-08 | 2002-02-13 | 华中科技大学 | 胰岛素口腔喷剂及其制备工艺 |
| KR100425755B1 (ko) | 2001-08-27 | 2004-04-03 | 주식회사 원진신약 | 이트라코나졸을 함유하는 조성물 및 그 제조방법 |
| PT1429731E (pt) | 2001-09-19 | 2007-04-30 | Elan Pharma Int Ltd | Formulações de insulina nanoparticulada |
| CA2463067A1 (en) | 2001-10-26 | 2003-05-08 | Sciclone Pharmaceuticals, Inc. | Pharmaceutical formulations comprising substituted xanthine compounds |
| CA2466851C (en) | 2001-11-26 | 2012-09-11 | Supergen, Inc. | Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions |
| US20060078618A1 (en) | 2001-12-11 | 2006-04-13 | Constantinides Panayiotis P | Lipid particles and suspensions and uses thereof |
| CA2841097A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin and g-csf fusion proteins |
| US6890961B2 (en) | 2002-02-01 | 2005-05-10 | Micelle Products, Inc. | Clear micellized formulations of β-carotene and method of treating leukoplakia |
| US20050287203A1 (en) | 2002-05-08 | 2005-12-29 | Nijs De H | Formulation comprising testosteron undecanoate and castor oil |
| CZ294371B6 (cs) | 2002-06-10 | 2004-12-15 | Pliva - Lachema, A. S. | Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy |
| FR2842736B1 (fr) | 2002-07-26 | 2005-07-22 | Flamel Tech Sa | Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s) |
| KR101195574B1 (ko) | 2002-09-24 | 2012-10-30 | 산토리 홀딩스 가부시키가이샤 | 아라키돈산을 단독으로 또는 도코사헥사엔산과의 조합으로함유하는 인지 능력 향상용 조성물 |
| US7411039B2 (en) | 2002-10-14 | 2008-08-12 | Novo Nordisk A/S | GLP-2 compounds, formulations, and uses thereof |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| BRPI0407276A (pt) | 2003-02-07 | 2006-01-31 | Prometic Biosciences Inc | ácidos graxos, glicerìdeos e análogos com comprimento de cadeia médio, como estimulantes de eritropoiese |
| US20070185194A1 (en) | 2003-07-01 | 2007-08-09 | Kamal Mehta | Stable oral compositions of azithromycin monohydrate |
| CN1972698B (zh) | 2003-09-01 | 2010-06-02 | 有限会社爱泽世 | β-羟基短-中链脂肪酸聚合物 |
| AU2004317954A1 (en) * | 2003-09-17 | 2005-10-13 | Chiasma, Inc. | Compositions capable of facilitating penetration across a biological barrier |
| ATE556598T1 (de) | 2003-10-10 | 2012-05-15 | Eisai R&D Man Co Ltd | Neue flüssige präparatezusammensetzung |
| AR046773A1 (es) | 2003-12-23 | 2005-12-21 | Novartis Ag | Formulaciones farmaceuticas de bisfosfonatos |
| US20050209441A1 (en) | 2004-03-22 | 2005-09-22 | Lile Jackson D | Process for promoting proper folding of human serum albumin using a human serum albumin ligand |
| CA2563533C (en) | 2004-04-15 | 2013-10-01 | Shmuel A. Ben-Sasson | Compositions capable of facilitating penetration across a biological barrier |
| US20070219131A1 (en) | 2004-04-15 | 2007-09-20 | Ben-Sasson Shmuel A | Compositions capable of facilitating penetration across a biological barrier |
| US20050256097A1 (en) | 2004-05-11 | 2005-11-17 | Kosan Biosciences, Inc. | Pharmaceutical solution formulations containing 17-AAG |
| WO2005117928A1 (en) | 2004-05-30 | 2005-12-15 | Cemines, Inc. | Compositions and methods for the treatment of skin cancer |
| US20060002989A1 (en) | 2004-06-10 | 2006-01-05 | Ahmed Salah U | Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same |
| JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
| CA2583413A1 (en) | 2004-09-21 | 2006-03-30 | Anesiva, Inc. | Delivery of polynucleotides |
| KR20080003322A (ko) * | 2005-02-24 | 2008-01-07 | 엘란 파마 인터내셔널 리미티드 | 도세탁셀 및 이의 유사체의 나노입자 배합물 |
| WO2006123360A2 (en) | 2005-03-01 | 2006-11-23 | Sun Pharmaceutical Industries Limited | Microspheres containing octreotide acetate |
| US7288520B2 (en) | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
| US20070021325A1 (en) | 2005-07-21 | 2007-01-25 | Mediplex Corporation | Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability |
| PT1903866E (pt) | 2005-11-07 | 2016-06-09 | Murty Pharmaceuticals Inc | Distribuição melhorada de tetra-hidrocanabinol |
| EP1988886A1 (en) | 2006-02-13 | 2008-11-12 | Intelgenx Corporation | Delayed release pharmaceutical oral dosage form and method of making same |
| US20070224142A1 (en) | 2006-03-22 | 2007-09-27 | Swaile David F | Hydrogenated castor oil based compositions as a replacement for petrolatum |
| MX2008012844A (es) | 2006-04-06 | 2009-01-19 | Activbiotics Pharma Llc | Composiciones farmaceuticas y usos de ellas. |
| BRPI0710503A2 (pt) | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| US8071136B2 (en) | 2006-04-21 | 2011-12-06 | Bioactives, Inc. | Water-soluble pharmaceutical compositions of hops resins |
| WO2007146234A2 (en) | 2006-06-09 | 2007-12-21 | Merrion Research Ii Limited | Solid oral dosage form containing an enhancer |
| US9241908B2 (en) | 2007-10-16 | 2016-01-26 | Biocon Limited | Orally administrable solid pharmaceutical composition and a process thereof |
| US20090280169A1 (en) | 2008-05-07 | 2009-11-12 | Merrion Research Iii Limited | Compositions of peptides and processes of preparation thereof |
| RU2678833C2 (ru) | 2008-09-17 | 2019-02-04 | Киазма Инк. | Фармацевтические композиции и соответствующие способы доставки |
-
2005
- 2005-04-14 CA CA2563533A patent/CA2563533C/en not_active Expired - Lifetime
- 2005-04-14 KR KR1020067023930A patent/KR20070044805A/ko not_active Withdrawn
- 2005-04-14 CN CNA2005800147113A patent/CN101084016A/zh active Pending
- 2005-04-14 MX MXPA06011871A patent/MXPA06011871A/es unknown
- 2005-04-14 JP JP2007507872A patent/JP2007532629A/ja active Pending
- 2005-04-14 US US11/105,763 patent/US20050232981A1/en not_active Abandoned
- 2005-04-14 WO PCT/IB2005/004183 patent/WO2006097793A2/en not_active Ceased
- 2005-04-14 AU AU2005329255A patent/AU2005329255B2/en not_active Expired
- 2005-04-14 US US11/547,568 patent/US8241670B2/en active Active
- 2005-04-14 NZ NZ550320A patent/NZ550320A/en not_active IP Right Cessation
- 2005-04-14 EP EP05857653A patent/EP1742663A2/en not_active Withdrawn
-
2006
- 2006-10-05 IL IL178479A patent/IL178479A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006097793A2 (en) | 2006-09-21 |
| US8241670B2 (en) | 2012-08-14 |
| NZ550320A (en) | 2010-02-26 |
| EP1742663A2 (en) | 2007-01-17 |
| AU2005329255B2 (en) | 2010-09-30 |
| MXPA06011871A (es) | 2007-10-08 |
| WO2006097793A3 (en) | 2006-12-21 |
| CN101084016A (zh) | 2007-12-05 |
| CA2563533C (en) | 2013-10-01 |
| AU2005329255A1 (en) | 2006-09-21 |
| KR20070044805A (ko) | 2007-04-30 |
| JP2007532629A (ja) | 2007-11-15 |
| IL178479A0 (en) | 2007-02-11 |
| US20050232981A1 (en) | 2005-10-20 |
| CA2563533A1 (en) | 2006-09-21 |
| US20080159984A1 (en) | 2008-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL178479A0 (en) | Compositions capable of facilitating penetration across a biological barrier | |
| GB2414666B (en) | Sanitizing composition and method of preparation | |
| IL177190A0 (en) | Medical suturing tool | |
| GB0422525D0 (en) | Dermatological compositions and methods | |
| PL1856374T3 (pl) | Kompozycja i sposób wytwarzania środka do podsadzki | |
| EP1729657A4 (en) | TISSUE CUTTING DEVICES AND RELATED METHODS | |
| IL180897A0 (en) | Method of producing a composition, composition and its use | |
| EG25421A (en) | Pesticidal composition and method for seed treatment | |
| IL177793A0 (en) | Method and composition for burned skin | |
| EG25768A (en) | Pesticidal composition and method for seed treatment | |
| GB0608398D0 (en) | Pharmaceutical composition and method of using same | |
| EP1768578A4 (en) | IMPROVED SURGICAL DRILL | |
| GB0422004D0 (en) | Method of deprotection | |
| ZA200706128B (en) | Pesticide compositions and methods | |
| IL177605A0 (en) | Macrolides and methods for producing same | |
| EP1765373A4 (en) | OZONIZED PHARMACEUTICAL COMPOSITION AND METHOD THEREOF | |
| ZA200605722B (en) | Composition and method | |
| IL178131A0 (en) | Surgical instrument and method | |
| AP2906A (en) | A composition and method for creation of ABME and uses thereof | |
| TWI367758B (en) | Composition comprising an epothilone and methods for producing a composition comprising an epothilone | |
| ZA200706038B (en) | Visco-supplement composition and methods | |
| GB0608399D0 (en) | Pharmaceutical composition and method of using same | |
| EP1812032A4 (en) | TISSUE FACTOR COMPOSITION AND RELATED METHODS | |
| GB0410250D0 (en) | Surgical instrument and method | |
| TWI316105B (en) | Compound drill and implement method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |